BEAM
Price
$21.91
Change
-$0.00 (-0.00%)
Updated
Nov 1 closing price
3 days until earnings call
JANX
Price
$54.39
Change
+$0.40 (+0.74%)
Updated
Nov 1 closing price
3 days until earnings call
Ad is loading...

BEAM vs JANX

Header iconBEAM vs JANX Comparison
Open Charts BEAM vs JANXBanner chart's image
Beam Therapeutics
Price$21.91
Change-$0.00 (-0.00%)
Volume$248
CapitalizationN/A
Janux Therapeutics
Price$54.39
Change+$0.40 (+0.74%)
Volume$572.93K
CapitalizationN/A
View a ticker or compare two or three
BEAM vs JANX Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
JANX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
BEAM vs. JANX commentary
Nov 02, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and JANX is a Hold.

COMPARISON
Comparison
Nov 02, 2024
Stock price -- (BEAM: $22.93 vs. JANX: $54.39)
Brand notoriety: BEAM and JANX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 93% vs. JANX: 92%
Market capitalization -- BEAM: $1.81B vs. JANX: $2.84B
BEAM [@Biotechnology] is valued at $1.81B. JANX’s [@Biotechnology] market capitalization is $2.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $494.31B to $0. The average market capitalization across the [@Biotechnology] industry is $2.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileJANX’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • JANX’s FA Score: 0 green, 5 red.
According to our system of comparison, both BEAM and JANX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 2 TA indicator(s) are bullish while JANX’s TA Score has 5 bullish TA indicator(s).

  • BEAM’s TA Score: 2 bullish, 6 bearish.
  • JANX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, JANX is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а +6.40% price change this week, while JANX (@Biotechnology) price change was +1.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 04, 2025.

JANX is expected to report earnings on Mar 07, 2025.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JANX($2.84B) has a higher market cap than BEAM($1.81B). JANX YTD gains are higher at: 406.897 vs. BEAM (-15.760). JANX has higher annual earnings (EBITDA): -63.86M vs. BEAM (-162.88M). BEAM has more cash in the bank: 1.01B vs. JANX (646M). JANX has less debt than BEAM: JANX (23.8M) vs BEAM (165M). BEAM has higher revenues than JANX: BEAM (353M) vs JANX (15.1M).
BEAMJANXBEAM / JANX
Capitalization1.81B2.84B64%
EBITDA-162.88M-63.86M255%
Gain YTD-15.760406.897-4%
P/E RatioN/AN/A-
Revenue353M15.1M2,338%
Total Cash1.01B646M156%
Total Debt165M23.8M693%
TECHNICAL ANALYSIS
Technical Analysis
BEAMJANX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 20 days ago
81%
Bullish Trend 6 days ago
87%
Declines
ODDS (%)
Bearish Trend 11 days ago
85%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
JANX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LCGJX30.360.35
+1.17%
William Blair Large Cap Growth R6
FAOFX16.980.17
+1.01%
Fidelity Advisor Series Growth Opps
MGQSX20.960.13
+0.62%
Morgan Stanley Inst Global Stars R6
HNCCX15.160.06
+0.40%
Hartford International Growth C
VWNDX23.510.03
+0.13%
Vanguard Windsor Investor Shares

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+4.66%
CRSP - BEAM
73%
Closely correlated
+9.42%
NTLA - BEAM
68%
Closely correlated
+4.15%
EDIT - BEAM
66%
Loosely correlated
+0.34%
PRME - BEAM
65%
Loosely correlated
+3.87%
DNLI - BEAM
65%
Loosely correlated
+4.20%
More

JANX and

Correlation & Price change

A.I.dvisor indicates that over the last year, JANX has been loosely correlated with VKTX. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if JANX jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JANX
1D Price
Change %
JANX100%
+0.74%
VKTX - JANX
64%
Loosely correlated
+0.47%
DNLI - JANX
56%
Loosely correlated
+4.20%
LGND - JANX
46%
Loosely correlated
+4.11%
BEAM - JANX
45%
Loosely correlated
+4.66%
CDXS - JANX
42%
Loosely correlated
+11.46%
More